Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys

Norman L. Letvin, Srinivas S. Rao, David C. Montefiori, Michael S. Seaman, Yue Sun, So Yon Lim, Wendy W. Yeh, Mohammed Asmal, Rebecca S. Gelman, Ling Shen, James B. Whitney, Cathal Seoighe, Miguel Lacerda, Sheila Keating, Philip J. Norris, Michael G. Hudgens, Peter B. Gilbert, Adam P. Buzby, Linh V. Mach, Jinrong ZhangHarikrishnan Balachandran, George M. Shaw, Stephen D. Schmidt, John Paul Todd, Alan Dodson, John R. Mascola, Gary J. Nabel

Research output: Contribution to journalArticlepeer-review


The RV144 vaccine trial in Thailand demonstrated that an HIV vaccine could prevent infection in humans and highlights the importance of understanding protective immunity against HIV. We used a nonhuman primate model to define immune and genetic mechanisms of protection against mucosal infection by the simian immunodeficiency virus (SIV). A plasmid DNA prime/recombinant adenovirus serotype 5 (rAd5) boost vaccine regimen was evaluated for its ability to protect monkeys from infection by SIVmac251 or SIVsmE660 isolates after repeat intrarectal challenges. Although this prime-boost vaccine regimen failed to protect against SIVmac251 infection, 50% of vaccinated monkeys were protected from infection with SIVsmE660. Among SIVsmE660-infected animals, there was about a one-log reduction in peak plasma virus RNA in monkeys expressing the major histocompatibility complex class I allele Mamu-A*01, implicating cytotoxic T lymphocytes in the control of SIV replication once infection is established. Among Mamu-A*01-negative monkeys challenged with SIVsmE660, no CD8 + T cell response or innate immune response was associated with protection against virus acquisition. However, low levels of neutralizing antibodies and an envelope-specific CD4+ T cell response were associated with vaccine protection in these monkeys. Moreover, monkeys that expressed two TRIM5 alleles that restrict SIV replication were more likely to be protected from infection than monkeys that expressed at least one permissive TRIM5 allele. This study begins to elucidate the mechanisms of vaccine protection against immunodeficiency viruses and highlights the need to analyze these immune and genetic correlates of protection in future trials of HIV vaccine strategies.

Original languageEnglish (US)
JournalScience translational medicine
Issue number81
StatePublished - May 4 2011
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys'. Together they form a unique fingerprint.

Cite this